YOINTY

Posology Adults (including the elderly):

The recommended dose is 2 capsules to be taken once a day (1,250 mg/day glucosamine). Glucosamine is not indicated for the treatment of acute pain. The relief of the pain may occur after several weeks of treatment, and sometimes after a longer time.

If no relief of pain occurs after 2-3 months, the continuation of the treatment should be re-evaluated.

Paediatric population:

YOINTY is not recommended for use in children below 18 years of age, due to a lack of data on safety and efficacy.

Hepatic and/or renal impairment:

In patients with impaired renal and/or liver function no dose recommendations can be given, since no studies have been performed.

Method of administration:

The capsules can be taken with or without food. The capsules should be swallowed whole without chewing, and with a sufficient amount of water.

The most common adverse reactions associated with treatment with glucosamine are described below. The reported adverse reactions are usually mild and transitory. System Organ Class Common (≥1/100 to <1/10) Uncommon (≥1/1,000 to ≤1/100) Not known (cannot be estimated from the available data) Nervous system disorders Headache Tiredness Dizziness Respiratory, thoracic and mediastinal disorders Asthma asthma aggravated Gastrointestinal disorders Nausea Abdominal pain Indigestion Diarrhoea Constipation Vomiting Skin and subcutaneous tissue disorders Rash, Itching, Flushing Angioedema Urticaria Metabolism and nutrition disorders Diabetes mellitus inadequate control Hypercholesterolaemia General disorders and administration site conditions Oedema Peripheral oedema Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk

YOINTY should not be used in children and adolescents below the age of 18, due to lack of data on safety and efficacy. A doctor should be consulted to rule out the presence of joint disease for which other treatment should be considered.

In patients with impaired glucose tolerance, monitoring of the blood glucose levels and, where relevant, insulin requirements is recommended before start of treatment and periodically during treatment. In patients with known risk factor for cardiovascular disease, monitoring of the blood lipid levels is recommended, since hypercholesterolemia has been reported in a few cases in patients treated with glucosamine.

A report on exacerbated asthma symptoms triggered after initiation of glucosamine therapy has been described (symptoms resolved after withdrawal of glucosamine). Asthmatic patients starting on glucosamine should therefore be aware of potential worsening of asthma symptoms.

1. YOINTY must not be given to patients who are allergic to shellfish as the active substance is obtained from shellfish.